-
-
-
-
-
-
-
Goldman Sachs Assumes Insmed (INSM) at Buy
-
-
-
-
-
-
-
Raymond James sees potential for beats across biopharma coverage
-
-
-
-
-
-
-
NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
-
-
-
-
-
-
-
Insmed (INSM) Tops Q1 EPS by 20c
-
-
-
-
-
-
-
Insmed (INSM) PT Lowered to $202 at Mizuho
-
-
-
-
-
-
-
Morgan Stanley Upgrades Insmed (INSM) to Overweight
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $230 at Jefferies
-
479,029 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


